Extension of the Therapeutic Window for Recombinant Tissue Plasminogen Activator With Argatroban in a Rat Model of Embolic Stroke
- 1 November 2001
- journal article
- Published by Wolters Kluwer Health in Stroke
- Vol. 32 (11) , 2635-2640
- https://doi.org/10.1161/hs1101.097390
Abstract
Background and Purpose— Argatroban, a specific thrombin inhibitor, has been shown to reduce ischemic lesion size after focal cerebral ischemia in rats. In addition, recombinant tissue plasminogen activator (rtPA) has been shown to reduce ischemic lesion size in both rats and humans if given within 3 hours of symptom onset. We tested the hypothesis that the administration of argatroban with rtPA could extend the treatment window of stroke to 4 hours without increasing gross cerebral hemorrhage rates or reducing efficacy.Keywords
This publication has 0 references indexed in Scilit: